Essa Pharma provides update on combination agreement with Xeno

ESSA Pharma (EPIX) announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics, a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of ESSA, ESSA received an amended Interim Order from the Supreme Court of British Columbia on September 25. The amended Interim Order approves the previously announced date for ESSA’s special meeting of the holders of common shares of the Company, optionholders and warrantholders of October 3 the deadline to deliver notices of dissent of October 1 the Court hearing date for approval of the Arrangement of October 7 and the deadline of October 3 for responses for persons intending to attend the October 7th hearing. ESSA’s Special Meeting will reconvene on October 3.